Valeant/Ackman Going Whole Hog On Zoetis As Plan B For Allergan?
This article was originally published in The Pink Sheet Daily
Executive Summary
Valeant investment partner William Ackman takes a stake in animal health company Zoetis in what could be a move to change strategies as Allergan continues to oppose Valeant’s offer.
You may also be interested in...
Investors Crow For Shares Of Zoetis As It Begins Trading On The NYSE
Zoetis makes its debut on the public stock exchange, garnering the highest priced IPO since Facebook began trading last year.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
Zafgen Drops Beloranib, But Its New Focus Raises Doubts
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.